Utrecht Centre for
Pharmaceutical Policy and Regulation
Tina Wang
Class of:
2016
Current affiliation:
CIRS
Contact:
Motivation:
My motivation to pursue research is to work towards a long term goal that my job will contribute to the continuous improvement of the healthcare system. I am particularly interested in investigating and developing tools and methods for the purpose of advancing regulatory and HTA policies and processes and facilitating equitable access to new medicinal products.
Education and experience:
Tina Wang is the Manager for the HTA programme at the Centre for Innovation in Regulatory Science (CIRS). The focus of her work was to advance international HTA and coverage body interaction with drug regulatory agencies in terms of scientific advice and alignment of technical requirements, to improve the understanding of HTA/Coverage processes and decision making and to promote best practice via the application of tools developed by CIRS over the past 30 years.
At CIRS, Ms Wang’s scope of responsibilities covers all aspect of HTA programme activities through marketing to delivery, including project managing the HTA programme and coordinating a HTA programme steering committee, executing and implementing of metrics studies evaluating the HTA process with in companies and agencies on annual basis, conducting independent literature research and designing specialised survey, and construction of and maintenance of the Regulatory and Reimbursement Atlas Programme.
She received her undergraduate degree in Applied Chemistry from the Beijing University of Technology and a Master of Science in Pharmaceutical Analysis and Quality Control from Kings College, University of London. Prior to joining CIRS in 2010, Ms Wang worked as a research scientist at Medpharm and GlaxoSmithKline. The focus of Tina’s master research and previous working experience was on the application of modern technology for analysis in drug discovery and development.
Ms Wang’s main field of interest is the international pharmaceutical strategy and policy in Regulatory Affair and Health Technology Assessment.
- M.Sc. (2007, King’s College London, UK) -Pharmaceutical Analysis & Quality Control
- B.Sc. (2005, Beijing University of Technology, China) – Applied Science – Chemistry
- Course in Pharmaceutical Economics and Policy (2014, LSE – London School of Economics and Political Science, UK)
- Course in Health Economic Evaluation (2011, University of Oxford, UK)
Title PhD project:
Ensuring equitable access to new medicine through quality Company, Regulatory and HTA decision making.
PhD project description:
Health technology assessment (HTA) is increasingly used to evaluate new medicines in order to inform coverage decision making for efficient allocation of healthcare resources. Beyond the traditional regulatory requirements of quality, efficacy and safety, HTA considers the effectiveness, appropriateness and cost of medicinal products and technologies. HTA agencies continuously evolve to adopt the best tools and techniques in order to make more efficient decisions about the place of new medicines in their jurisdiction. Initiatives are ongoing amongst HTA agencies and other stakeholders such as regulatory bodies, academic groups and industry to discuss common methodologies, guidelines, standard processes and good review practices, in order to identify criteria for best practices in HTA decision making.
However, the variability in remits of HTA organisations and methodologies that are utilised in HTA appraisal and coverage decision-making processes in different countries results in a complex and challenging environment, as well as inequitable access to new medicines for patients.
This research is aimed to evaluate the influence of HTA requirements on development as well as, timelines, procedures and transparency, with the purpose to understand and improve the HTA decision making process within companies and agencies. The research will explore the stakeholder interactions between company, regulatory and HTA agencies in terms of early scientific advice, the commonality of evidentiary requirement between regulatory and HTA stakeholders, as well investigate the good HTA decision making practices by agencies and good submission practice from companies is to understand just how companies can build quality submission and how agencies can build quality into the HTA process and decision making.
Teammembers and other people involved:
Dr Neil McAuslane, Center for Innovation in Regulatory Science (The United Kingdom), Prof. Dr. Bert Leufkens, Dr Anke Hövels
Publications: